Premarin’s 84-year hold on the market ends as FDA approves a generic versionTrade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer January 23, 2026Vol.52 No.03By Claire Marie Porter
Capitol Hill Spending bill passed by the House gives NIH $415M raise, NCI gets $128MLegislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched January 23, 2026Vol.52 No.03By Jacquelyn Cobb
Capitol Hill Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill January 23, 2026Vol.52 No.03By Jacquelyn Cobb
Guest Editorial Blood Cancer United: A new name at the right moment January 23, 2026Vol.52 No.03By E. Anders Kolb
Sponsored Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community January 23, 2026Vol.52 No.03By Tanya Dorff
FreeIn the Archives Bernie Lewinsky’s collection of artifacts captures “the learning curve” of radiation oncology January 23, 2026Vol.52 No.03By Sara Willa Ernst
News Analysis ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook January 16, 2026Vol.52 No.02By Jacquelyn Cobb and Paul Goldberg
Health Equity New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years January 16, 2026Vol.52 No.02By Sara Willa Ernst
FreeGuest Editorial When “safe and effective” is not “reasonable and necessary”We can curb excessive drug dosing and improve the quality of cancer care January 16, 2026Vol.52 No.02By Mark J. Ratain and David A. Hyman
Trials & Tribulations A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers January 16, 2026Vol.52 No.02By Kevin King
